These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 17531517)

  • 1. Modelling the restoration of wild-type dynamic behaviour in DeltaF508-CFTR NBD1 by 8-cyclopentyl-1,3-dipropylxanthine.
    Warner DJ; Vadolia MM; Laughton CA; Kerr ID; Doughty SW
    J Mol Graph Model; 2007 Oct; 26(3):691-9. PubMed ID: 17531517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure.
    Lewis HA; Zhao X; Wang C; Sauder JM; Rooney I; Noland BW; Lorimer D; Kearins MC; Conners K; Condon B; Maloney PC; Guggino WB; Hunt JF; Emtage S
    J Biol Chem; 2005 Jan; 280(2):1346-53. PubMed ID: 15528182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
    Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
    Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the interactions between nucleotide binding domains and membrane spanning domains in cystic fibrosis transmembrane regulator: A molecular dynamic study.
    Belmonte L; Moran O
    Biochimie; 2015 Apr; 111():19-29. PubMed ID: 25640670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function.
    Rabeh WM; Bossard F; Xu H; Okiyoneda T; Bagdany M; Mulvihill CM; Du K; di Bernardo S; Liu Y; Konermann L; Roldan A; Lukacs GL
    Cell; 2012 Jan; 148(1-2):150-63. PubMed ID: 22265408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2009 Oct; 48(41):9882-90. PubMed ID: 19761259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human-mouse cystic fibrosis transmembrane conductance regulator (CFTR) chimeras identify regions that partially rescue CFTR-ΔF508 processing and alter its gating defect.
    Dong Q; Ostedgaard LS; Rogers C; Vermeer DW; Zhang Y; Welsh MJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(3):917-22. PubMed ID: 22210114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminished self-chaperoning activity of the DeltaF508 mutant of CFTR results in protein misfolding.
    Serohijos AW; Hegedus T; Riordan JR; Dokholyan NV
    PLoS Comput Biol; 2008 Feb; 4(2):e1000008. PubMed ID: 18463704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain.
    Odolczyk N; Fritsch J; Norez C; Servel N; da Cunha MF; Bitam S; Kupniewska A; Wiszniewski L; Colas J; Tarnowski K; Tondelier D; Roldan A; Saussereau EL; Melin-Heschel P; Wieczorek G; Lukacs GL; Dadlez M; Faure G; Herrmann H; Ollero M; Becq F; Zielenkiewicz P; Edelman A
    EMBO Mol Med; 2013 Oct; 5(10):1484-501. PubMed ID: 23982976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of NBD1 thermal stability is necessary and sufficient to correct ∆F508 CFTR folding and assembly.
    He L; Aleksandrov AA; An J; Cui L; Yang Z; Brouillette CG; Riordan JR
    J Mol Biol; 2015 Jan; 427(1):106-20. PubMed ID: 25083918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of protein kinase CK2 closes the CFTR Cl channel, but has no effect on the cystic fibrosis mutant deltaF508-CFTR.
    Treharne KJ; Xu Z; Chen JH; Best OG; Cassidy DM; Gruenert DC; Hegyi P; Gray MA; Sheppard DN; Kunzelmann K; Mehta A
    Cell Physiol Biochem; 2009; 24(5-6):347-60. PubMed ID: 19910675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis.
    Srivastava M; Eidelman O; Pollard HB
    Mol Med; 1999 Nov; 5(11):753-67. PubMed ID: 10656877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into interactions between the nucleotide-binding domain of CFTR and keratin 8.
    Premchandar A; Kupniewska A; Bonna A; Faure G; Fraczyk T; Roldan A; Hoffmann B; Faria da Cunha M; Herrmann H; Lukacs GL; Edelman A; Dadlez M
    Protein Sci; 2017 Feb; 26(2):343-354. PubMed ID: 27870250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR evidence for differential phosphorylation-dependent interactions in WT and DeltaF508 CFTR.
    Kanelis V; Hudson RP; Thibodeau PH; Thomas PJ; Forman-Kay JD
    EMBO J; 2010 Jan; 29(1):263-77. PubMed ID: 19927121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508.
    DeCarvalho AC; Gansheroff LJ; Teem JL
    J Biol Chem; 2002 Sep; 277(39):35896-905. PubMed ID: 12110684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain.
    Hoelen H; Kleizen B; Schmidt A; Richardson J; Charitou P; Thomas PJ; Braakman I
    PLoS One; 2010 Nov; 5(11):e15458. PubMed ID: 21152102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry.
    Lewis HA; Wang C; Zhao X; Hamuro Y; Conners K; Kearins MC; Lu F; Sauder JM; Molnar KS; Coales SJ; Maloney PC; Guggino WB; Wetmore DR; Weber PC; Hunt JF
    J Mol Biol; 2010 Feb; 396(2):406-30. PubMed ID: 19944699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator.
    Chen EY; Bartlett MC; Loo TW; Clarke DM
    J Biol Chem; 2004 Sep; 279(38):39620-7. PubMed ID: 15272010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment of the ion transport defect in cystic fibrosis.
    Roomans GM
    Expert Opin Investig Drugs; 2001 Jan; 10(1):1-19. PubMed ID: 11116277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory insertion removal restores maturation, stability and function of DeltaF508 CFTR.
    Aleksandrov AA; Kota P; Aleksandrov LA; He L; Jensen T; Cui L; Gentzsch M; Dokholyan NV; Riordan JR
    J Mol Biol; 2010 Aug; 401(2):194-210. PubMed ID: 20561529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.